Enimmune corporation
6564
Rank in Stocks
#24553
Enimmune Corporation is a Taiwanese biopharmaceutical company primarily focused... Enimmune Corporation is a Taiwanese biopharmaceutical company primarily focused on the research, development, and commercialization of pharmaceutical products. Among its key offerings is Tuberculin PPD RT23 SSI, an approved diagnostic agent utilized in tuberculin tests to ascertain the presence of tuberculosis infection in patients. Beyond its existing products, Enimmune is heavily invested in developing vaccines aimed at combating a diverse array of infectious diseases. These include, but are not limited to, vaccines for enterovirus, pneumonia, norovirus, dengue fever, and Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Established in 2014, the company maintains its headquarters in Taichung City, Taiwan.
Share Price
$0.4450731
Last synced: 2026-11-10
Market Cap
$32.25M
Change (1 day)
-2.34%
Change (1 year)
-32.85%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Enimmune corporation (6564)
Category
Healthcare
Operating Margin for Enimmune corporation (6564)
Operating Margin as of November 2026 TTM: -232.49%
According to Enimmune corporation's latest financial reports, its current operating margin (TTM) is -232.49%. At the end of 2025 the company had an operating margin of -384.37%.
Operating Margin history for Enimmune corporation from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -232.49% | -39.51% |
| 2025 | -384.37% | 1.41% |
| 2024 | -379.02% | -32.29% |
| 2023 | -559.79% | 268.26% |
| 2022 | -152.01% | 184.56% |
| 2021 | -53.42% | -85.23% |
| 2020 | -361.61% | -90.22% |
| 2019 | -3,696.81% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.17% |
US
|
|
| -149.01% | -99.36% |
US
|
|
| 25.57% | -100.11% |
AU
|
|
| 31.23% | -100.13% |
BE
|
|
| 29.35% | -100.13% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Enimmune corporation's operating margin
What is Enimmune corporation's operating margin?
Enimmune corporation's operating margin is -232.49%, as of Nov 2026.
What was Enimmune corporation's operating margin in 2025?
In 2025, Enimmune corporation's operating margin was -384.37%, compared with -379.02% in 2024.
How has Enimmune corporation's operating margin changed since 2020?
From 2020 to 2025, Enimmune corporation's operating margin was highest in 2021 (-53.42%) and lowest in 2023 (-559.79%).
How does Enimmune corporation's operating margin compare with similar companies?
Enimmune corporation's operating margin (-232.49%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.